ImProDia Ltd.

www.improdia.co.il

High-Tech Company

Suspended Operations Q4/2023

TECH VERTICALS

Biotechnology, Diagnostics, Life Sciences, MedTech

General Data

Sector	Biomed
Company Stage:	R&D
Established	2012
Number of Employees	5
Reg. Number:	abCDe

DESCRIPTION

ImProDia is an innovative diagnostic company which uses novel inflammatory biomarker technology to pinpoint disease status and progression.
The company has discovered and patented revolutionary biomarkers and designed a flow cytometry-based prognostic, diagnostic kit for evaluating patients’ immune function. ImProDia's goal is to promote implementation of the novel biomarkers in the clinic thus, improving treatment with immune system modulating therapies, by means of a simple blood test for patients with chronic disease.

TECHNOLOGY

ImProDia technology is based upon mixing blood samples in a combination of buffers and Fluorophore-labeled specific antibodies recognizing the biomarkers and different cell types of the immune system. The samples are then analyzed by Flow cytometer equipped with multiple laser design for multicolor analysis. The software translates the fluorescent intensity levels to histograms. Relative expression levels of the biomarkers will indicate whether the patient suffers from chronic inflammation and impaired immune function, or whether the therapy affected the immune function and follow diseases regression or recurrence.

Products and Phases

Product	Phase
Dia-ImPro-Test	Phase I
Dia-ImPro-Test kit, designed to evaluate the immune system functionality in diabetes type II patients. In the US and Canada alone, there is a total of about 27,500,000 people diagnosed as diabetes type II patients, in Europe about 37,000,000 and in the rest of the world about 130,000,000. According to these numbers and based on the recommendations of the American Diabetes Association that people with diabetes will be monitored two to four times a year, we forecast selling millions of ImProDia's test upon approval of the kit. Clinical results in diabetic patients demonstrate the advantages of ImProDia’s novel biomarkers compared with the golden standard CRP and Hba1c tests. Initial clinical studies on cancer patients show the capacity of the novel biomarkers to evaluate the patients’ immune status, distinguish between responder vs. no-responder patients to applied immune-based therapies, and follow disease regression or progression. • ImProDia has received grant approvals from the Massachusetts-Israel Industrial R&D Cooperation Framework, and from CSO of Israeli industry and commerce ministry.

	TARGET MARKETS
	Patients displaying diseases such as autoimmune disorders (diabetes, rheumatoid arthritis, Crhons), chronic infections (HIV, Leprosy, Lehishmania) and cancer, are characterized by chronic inflammation that leads to immunosuppression.

	BUSINESS MODEL
	B2C

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Accounting Firm

REMARKS

Date	Remark
22/09/2014	Results in Diabetes Human study. Currently on going Human studies on Melanoma cancer and Colorectal cancer. Negotiations with Pharma companies for collaboration. Contact with VC's for investment. The company is currently looking for small and larger investors ranging from $250 thousand dollars to $3 million.

CONTACT INFO

Expand / Collapse All

Main Address: Herzliya, Israel

Address	6 Hahoshlim St.
POB	12006
City	Herzliya
Country	Israel
Zip	4672406

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Prof. Michal Baniyash	Co-Founder	Goldman Bio (Advisory Board Member)
Dr. Yair Klieger	Co-Founder
Dr. Raphael Nir	Co-Founder
Mr. Tuvia Sofinzon	Co-Founder
Ms. Monica Wolmer	CFO

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

First Round

Jun. 01, 2019

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Holding Company	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe

Seed - Extended

Oct. 15, 2014

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Holding Company	abCDe
abC Defghij	Private Investor	abCDe

Seed

Jun. 01, 2012

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Holding Company	abCDe
abC Defghij	Technology Transfer Company	abCDe
abC Defghij	Private Investor	abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jun. 19, 2012

Seed

abCDe

SBH Sciences and Improdia of Israel will work together toward the development of an immunosuppression prognostic kit. SBH will receive $184,000 from the Massachusetts Life Sciences Center and Improdia will receive $202,000 from OCS.

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Bi-National Fund	abCDe

Last Updated:	abCDe
IVC Number:	abCDe